CagriSema (Cagrilintide + Semaglutide)Metabolic CombinationBlendSafety Rating 7/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Modern AminosBest $/mgCOA ✓ · 3P | $124.00 | $12.40 | May 14, 2026 | Buy → |
Overview
About CagriSema
Mechanism of action
Combination of cagrilintide (amylin agonist) and semaglutide (GLP-1 agonist); dual mechanism targets appetite, gastric emptying, and satiety via complementary central and peripheral pathways; demonstrated greater weight loss than either alone.
Safety profile
Nausea, vomiting, diarrhea (additive GI effects vs. either alone); injection site reactions; constipation. Profile similar to GLP-1 class. · Strong Phase III data; GI side effects similar to semaglutide; regulatory review ongoing
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops CagriSema below your target.
Related pages
More on CagriSema
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Fixed-ratio combination of cagrilintide (amylin analogue) + semaglutide (GLP-1 agonist) in a once-weekly subcutaneous injection — dual complementary mechanisms targeting satiety, gastric emptying, and energy expenditure.
- REIMAGINE Phase 2/3 trials demonstrated ~25% mean body weight loss at 68 weeks, with significant improvements in HbA1c, waist circumference, and blood pressure.